Rep. Gilbert Ray Cisneros, Jr. Buys Stryker Corporation (NYSE:SYK) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Stryker stock on December 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Stryker Price Performance

Shares of Stryker stock traded up $2.99 during trading on Wednesday, reaching $358.81. The company’s stock had a trading volume of 1,794,990 shares, compared to its average volume of 1,537,326. The stock has a 50-day moving average price of $359.85 and a two-hundred day moving average price of $374.37. The stock has a market capitalization of $137.22 billion, a P/E ratio of 47.15, a price-to-earnings-growth ratio of 2.28 and a beta of 0.89. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.87 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. This is a boost from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. Stryker’s dividend payout ratio is 46.25%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SYK shares. Truist Financial cut their price target on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Needham & Company LLC reissued a “buy” rating and set a $448.00 price objective on shares of Stryker in a report on Friday, November 14th. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a research note on Tuesday, January 6th. The Goldman Sachs Group set a $399.00 price target on shares of Stryker in a research report on Friday, January 9th. Finally, Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Fourteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $430.00.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 522,118 shares of company stock worth $185,381,932 in the last 90 days. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

Several hedge funds have recently added to or reduced their stakes in SYK. Embree Financial Group bought a new stake in Stryker during the 4th quarter worth about $207,000. MeadowBrook Investment Advisors LLC boosted its holdings in shares of Stryker by 2.1% during the 4th quarter. MeadowBrook Investment Advisors LLC now owns 4,638 shares of the medical technology company’s stock worth $1,630,000 after buying an additional 96 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Stryker by 3.8% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 12,852 shares of the medical technology company’s stock worth $4,517,000 after acquiring an additional 469 shares during the period. Goelzer Investment Management Inc. boosted its stake in Stryker by 14.1% in the 4th quarter. Goelzer Investment Management Inc. now owns 1,415 shares of the medical technology company’s stock valued at $497,000 after purchasing an additional 175 shares during the period. Finally, AMI Investment Management Inc. grew its stake in shares of Stryker by 1.9% in the fourth quarter. AMI Investment Management Inc. now owns 11,274 shares of the medical technology company’s stock valued at $3,962,000 after acquiring an additional 208 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.